Skip to main content
Erschienen in: Breast Cancer Research 1/2020

Open Access 01.12.2020 | Correction

Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study

verfasst von: Danielle H. Bodicoat, Minouk J. Schoemaker, Michael E. Jones, Emily McFadden, James Griffin, Alan Ashworth, Anthony J. Swerdlow

Erschienen in: Breast Cancer Research | Ausgabe 1/2020

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​bcr3613
Correction to: Breast Cancer Res
https://doi.org/10.1186/bcr3613
As a consequence of responding to colleagues who asked about the publication of the original article [1], the authors have determined that the data published in Table 4 of the paper are incorrect. A number of moderate to strong correlations were identified in the corrected data that were not identified in the original manuscript.
The corrected table is shown below. These corrections affect the following sentences in the Discussion, but do not affect the remainder of the findings in the paper, or the summary of data in the Abstract.
The following sentences in the Discussion “Table 4 shows that the correlation between event timing was low in most instances. Interestingly, the duration between thelarche and menarche was not correlated with age at thelarche or age at menarche, but was highly correlated with age at regular periods, but not with age at menarche or age at regular periods. These high correlations suggest that these risk factors may be acting through the same pathway as each other or one may be a marker for the other” should be replaced by
“Table 4shows that the duration between thelarche and menarche was only modestly correlated (− 0.37 and 0.39) with age at thelarche or age at menarche, and was poorly correlated with age at regular periods (0.19). Strong (> 0.70) correlations were observed, however, for age at regular periods with respect to durations to this age from thelarche and menarche, for the duration between menarche and reaching adult height with age at reaching adult height, between the duration from menarche to regular periods and from thelarche to regular periods, and between ages at menarche and thelarche”
Table 4
Pearson’s correlations between timing pubertal variables
 
Age at thelarche
Age at menarche
Age at first regular periods
Age reached adult height
Years between thelarche and menarche
Years between thelarche and first regular periods
Years between menarche and first regular periods
Age at menarche
0.71
      
Age at regular periods
0.30
0.44
     
Age reached adult height
0.33
0.33
0.15
    
Years between thelarche and menarche
−0.37
0.39
0.19
0.02
   
Years between thelarche and first regular periods
−0.19
0.18
0.80
0.03
0.49
  
Years between menarche and first regular periods
−0.004
− 0.01
0.79
0.02
−0.007
0.87
 
Years between menarche and reaching adult height
−0.19
−0.38
− 0.17
0.75
− 0.25
−0.09
0.03
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study
verfasst von
Danielle H. Bodicoat
Minouk J. Schoemaker
Michael E. Jones
Emily McFadden
James Griffin
Alan Ashworth
Anthony J. Swerdlow
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/2020
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-020-1257-2

Weitere Artikel der Ausgabe 1/2020

Breast Cancer Research 1/2020 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.